বাংলাদেশ -
ইংরেজি -
DGDA (Directorate General of Drug Administration)
ascobex 250 tablet
beximco pharmaceuticals ltd. - vitamin c - tablet - 250 mg
ফিলিপাইন -
ইংরেজি -
FDA (Food And Drug Administration)
ascanex 50mg lyophilized powder for solution for infusion
progen pharmaceutical distributors; distributor: progen pharmaceutical distributors - caspofungin (as acetate) - lyophilized powder for solution for infusion - 50mg
ভারত -
ইংরেজি -
Central Drugs Standard Control Organization
ascodex plus 100 ml syr
glenmark - diphenhydramine hcl.,bromhexine hcl.,guaiphenesin,amm.chl.,menthol - syr - 8,4,50,100,1;mg;5ml - 100 ml
নাইজেরিয়া -
ইংরেজি -
NAFDAC (National Agency for Food and Drugs Administration and Control)
ascorex syrup (pom)
salbutamol 2mg, bromhexine hcl 4mg, guaifenesin 100mg, menthol 1mg/1ml
নাইজেরিয়া -
ইংরেজি -
NAFDAC (National Agency for Food and Drugs Administration and Control)
ascorex expectorant (pom)
salbutamol sulphate 2mg,bromhexine hcl 4mg,guaifensin usp 100mg,menthol 1mg/100ml
বাংলাদেশ -
ইংরেজি -
DGDA (Directorate General of Drug Administration)
ascorex liquid
aksim laboratories (ayurvedic) - aswagandharista - liquid
বাংলাদেশ -
ইংরেজি -
DGDA (Directorate General of Drug Administration)
alconex liquid
neuron drug laboratories (unani) - sharbat buzuri - liquid
মার্কিন যুক্তরাষ্ট্র -
ইংরেজি -
NLM (National Library of Medicine)
taclonex- calcipotriene and betamethasone dipropionate ointment
physicians total care, inc. - calcipotriene hydrate (unii: s7499tyy6g) (calcipotriene - unii:143nq3779b), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - calcipotriene 50 ug in 1 g - taclonex® (calcipotriene and betamethasone dipropionate) ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older for up to 4 weeks. - taclonex® ointment should not be applied to the face, axillae or groin. - taclonex® ointment should not be used if there is skin atrophy at the treatment site. none. teratogenic effects: pregnancy category c there are no adequate and well-controlled studies in pregnant women. pregnant women were excluded from the clinical studies conducted with taclonex® ointment. taclonex® ointment should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. animal reproduction studies have not been conducted with taclonex® ointment. taclonex® ointment contains calcipotriene that has been shown to be fetotoxic and betamethasone dipropionate that has been shown to be teratogenic in animals when given systemically. teratogenicity studies with calcipotriene were performed by the